Discover how Ergomed’s adaptable approach enabled a small biotech to advance its Phase I/II Clinical Trial for Advanced Clear Cell Renal Cell Carcinoma (RCC), evaluating an innovative oral CXCR4 inhibitor.

 

Faced with costly delays, this startup relied on Ergomed’s expertise to create and rapidly launch a concurrent “sister study”, maximizing efficiency and maintaining timelines.

Learn how Ergomed’s quick thinking and strategic execution provided essential support, helping the study proceed smoothly and gathering critical data for future development. Download the full case study to see how Ergomed empowers small biotechs to thrive in challenging clinical trials.

 

Download Case Study
Phase I/II study – Oncology and Renal Diseases, specifically targeting Advanced Clear Cell RCC